NCT05404139: Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
- State
- Under way
- Phase
- Phase 2
- People
- 352 planned
- Started
- 24 May 2023
- Primary completion
- Feb 2031
- Arms
- Arm 4: Study Treatment (Abiraterone + Atorvastatin)
- Results
- None posted
- 3 Jun 2022: Trial registered
- 24 May 2023: Trial started